Advertisement
Original Article| Volume 62, ISSUE 9, P954-962, November 01, 2007

The Neuropsychological Effects of Chronic Methylphenidate on Drug-Naive Boys with Attention-Deficit/Hyperactivity Disorder

  • David R. Coghill
    Correspondence
    Address reprint requests to David R. Coghill, M.B., Ch. B., Section of Psychiatry and Behavioral Sciences, Division of Pathology and Neuroscience, University of Dundee, Ninewells Medical School, Dundee, DD1 9SY, UK
    Affiliations
    Section of Psychiatry and Behavioral Sciences, Division of Pathology and Neuroscience, University of Dundee, Ninewells Medical School, Dundee, United Kingdom.
    Search for articles by this author
  • Sinead M. Rhodes
    Affiliations
    Section of Psychiatry and Behavioral Sciences, Division of Pathology and Neuroscience, University of Dundee, Ninewells Medical School, Dundee, United Kingdom.
    Search for articles by this author
  • Keith Matthews
    Affiliations
    Section of Psychiatry and Behavioral Sciences, Division of Pathology and Neuroscience, University of Dundee, Ninewells Medical School, Dundee, United Kingdom.
    Search for articles by this author

      Background

      The reported neuropsychological effects of methylphenidate (MPH) in attention-deficit/hyperactivity disorder (ADHD) are inconsistent. The assumed relationships between these neuropsychological effects and clinical efficacy have not been substantiated. We therefore investigated the effects of chronic MPH administration on neuropsychological functioning.

      Methods

      We conducted a 12-week, placebo-controlled, double-blinded, randomized, crossover trial (MPH .3 and .6 mg/kg/dose and placebo). Participants were 75 boys aged 7–15 years with ADHD. Neuropsychological performance was assessed with tests taken from the Cambridge Neuropsychological Test Automated Battery (CANTAB) battery and a GoNoGo task.

      Results

      Chronic MPH improved performance (p < .001) on aspects of the GoNoGo task (p < .02) and on three CANTAB tasks which together contributed to a “recognition memory” component identified through principal components analysis (delayed matching to sample [DMtS], pattern and spatial recognition). There were no effects on other, high or low “executive demand” tasks (p > .05). GoNoGo performance improvements were the only neuropsychopharmacological changes associated with clinical response. Poor performance on the DMtS task was the sole baseline neuropsychological predictor of clinical response.

      Conclusions

      Chronic MPH predominantly enhanced neuropsychological functioning on “recognition memory” component tasks with modest “executive” demands. Neuropsychological measures offer only modest contributions to the prediction of clinical responses to MPH in ADHD.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Psychiatric Association
        Diagnostic and statistical manual of mental disorders.
        4th ed. American Psychiatric Association, Washington, D.C1994
        • Barkley R.A.
        ADHD and the nature of self-control.
        Guilford Press, New York1997
        • Barnett R.
        • Maruff P.
        • Vance A.
        • Luk E.S.L.
        • Costin J.
        • Wood C.
        • et al.
        Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory.
        Psychological Med. 2001; 31: 1107-1115
        • Bedard A.C.
        • Martinussen R.
        • Ickowicz A.
        • Tannock R.
        Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder.
        J Am Acad Child Adolesc Psychiatry. 2004; 43: 260-268
        • Berman T.
        • Douglas V.I.
        • Barr R.G.
        Effects of methylphenidate on complex cognitive processing in attention-deficit hyperactivity disorder.
        J Abnorm Psychology. 1999; 108: 90-105
        • Buitelaar J.K.
        • van der Gaag R.J.
        • Swaab-Barneveld H.
        • Kuiper M.
        Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder.
        J Am Acad Child Adolesc Psychiatry. 1995; 34: 1025-1032
        • Castellanos F.X.
        • Tannock R.
        Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes.
        Nat Rev Neurosci. 2002; 3: 617-628
        • Coghill D.
        • Nigg J.
        • Rothenberger A.
        • Sonuga-Barke E.
        • Tannock R.
        Whither causal models in the neuroscience of ADHD?.
        Dev Sci. 2005; 8: 105-114
        • Conners C.K.
        Conners’ Rating Scales-Revised Technical Manual.
        Multi-Health Systems, Inc, North Tonawanda, NY1997
        • Denney C.B.
        • Rapport M.D.
        Predicting methylphenidate response in children with ADHD: theoretical, empirical, and conceptual models.
        J Am Acad Child Adolesc Psychiatry. 1999; 38: 393-401
        • Douglas V.I.
        Cognitive control processes in attention-deficit/hyperactivity disorder.
        in: Quay H.C. Hogan A.E. Handbook of disruptive behavior disorders. Plenum Press, New York1999: 105-138
        • Dunn L.
        • Dunn L.
        • Whetton C.
        • Burley J.
        British Picture Vocabulary Scale.
        2nd ed. NFER-Nelson, London1997
        • Elliott R.
        • Sahakian B.J.
        • Matthews K.
        • Bannerjea A.
        • Rimmer J.
        • Robbins T.W.
        Effects of methylphenidate on spatial working memory and planning in healthy young adults.
        Psychopharmacology. 1997; 131: 196-206
        • Gao W.J.
        • Goldman-Rakic P.S.
        Selective modulation of excitatory and inhibitory microcircuits by dopamine.
        Proc Natl Acad Sci USA. 2003; 100: 2836-2841
        • Greenhill L.L.
        • Halperin J.M.
        • Abikoff H.
        Stimulant medications.
        J Am Acad Child Adolesc Psychiatry. 1999; 38: 503-512
        • Jacobson N.S.
        • Truax P.
        Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.
        J Consult Clin Psychol. 1991; 59: 12-19
        • Kempton S.
        • Vance A.
        • Maruff P.
        • Luk E.
        • Costin J.
        • Pantelis C.
        Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children.
        Psychological Med. 1999; 29: 527-538
        • Lowe C.
        • Rabbitt P.
        Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues.
        Neuropsychologia. 1998; 36: 915-923
        • Mehta M.A.
        • Goodyer I.M.
        • Sahakian B.J.
        Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity.
        J Child Psychol Psychiatry. 2004; 45: 293-305
        • Mehta M.A.
        • Owen A.M.
        • Sahakian B.J.
        • Mavaddat N.
        • Pickard J.D.
        • Robbins T.W.
        Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain.
        J Neurosci. 2000; 20: RC65
        • Morris R.C.
        • Evendon J.L.
        • Sahakian B.J.
        • Robbins T.W.
        Computer-aided assessment of dementia: Comparative studies of neuropsychological deficits in Alzheimer-type dementia and Parkinson’s disease.
        in: Stahl S.M. Iversen S.D. Goodman E.C. Cognitive Neurochemistry. Oxford University Press, Oxford1987: 21-36
        • National Institute of Mental Health
        Clinical Global Impressions.
        Psychopharmacol Bull. 1985; 21: 839-843
        • Owen A.M.
        • Sahakian B.J.
        • Semple J.
        • Polkey C.E.
        • Robbins T.W.
        Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man.
        Neuropsychologia. 1995; 33: 1-24
        • Rabbitt P.
        Introduction: Methodologies and Models in the Study of Executive function.
        in: Rabbitt P. Methodology of frontal and executive function. Psychology Press Ltd, Hove, EastSussex, UK1997: 1-38
        • Rapport M.D.
        • Kelly K.L.
        Psycho-stimulant effects on learning and cognitive function: findings and implications for children with attention deficit hyperactivity disorder.
        Clin Psychology Rev. 1991; 11: 61-92
        • Rhodes S.M.
        • Coghill D.R.
        • Matthews K.
        Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder.
        Psychopharmacology (Berl). 2004; 175: 319-330
        • Rhodes S.M.
        • Coghill D.R.
        • Matthews K.
        Neuropsychological functioning in stimulant-naive boys with hyperkinetic disorder.
        Psychol Med. 2005; 35: 1109-1120
        • Rhodes S.M.
        • Coghill D.
        • Matthews K.
        Acute neuropsychological effects of the psychostimulant methylphenidate in drug naive boys with ADHD.
        J Child Psychol Psychiatry. 2006; 47: 1184-1194
        • Robbins T.W.
        • Sahakian B.J.
        “Paradoxical” effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioral pharmacology.
        Neuropharmacology. 1979; 18: 931-950
        • Ross R.G.
        • Hommer D.
        • Breiger D.
        • Varley C.
        • Radant A.
        Eye movement task related to frontal lobe functioning in children with attention deficit disorder.
        J Am Acad Child Adolesc Psychiatry. 1994; 33: 869-874
        • Safer D.J.
        • Malever M.
        Stimulant treatment in Maryland public schools.
        Pediatrics. 2000; 106: 533-539
        • Scheres A.
        • Oosterlaan J.
        • Swanson J.
        • Morein-Zamir S.
        • Meiran N.
        • Schut H.
        • et al.
        The effect of methylphenidate on three forms of response inhibition in boys with AD/HD.
        J Abnorm Child Psychol. 2003; 31: 105-120
        • Shue K.L.
        • Douglas V.I.
        Attention deficit hyperactivity disorder and the frontal lobe syndrome.
        Brain Cogn. 1992; 20: 104-124
        • Sonuga-Barke E.J.
        The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics.
        Neurosci Biobehav Rev. 2003; 27: 593-604
        • Taylor E.
        • Schachar R.
        • Thorley G.
        • Wieselberg H.M.
        • Everitt B.
        • Rutter M.
        Which boys respond to stimulant medication?.
        Psychol Med. 1987; 17: 121-143
        • Toplak M.E.
        • Rucklidge J.J.
        • Hetherington R.
        • John S.C.
        • Tannock R.
        Time perception deficits in attention-deficit/hyperactivity disorder and comorbid reading difficulties in child and adolescent samples.
        J Child Psychol Psychiatry. 2003; 44: 888-903
        • Trommer B.L.
        • Hoeppner J.A.
        • Zecker S.G.
        The go-no go test in attention deficit disorder is sensitive to methylphenidate.
        J Child Neurol. 1991; 6: S128-S131
        • Van der Meere J.
        • Gunning B.
        • Stemerdink N.
        The effect of methylphenidate and clonidine on response inhibition and state regulation in children with ADHD.
        J Child Psychol Psychiatry. 1999; 40: 291-298
        • Willcutt E.G.
        • Doyle A.E.
        • Nigg J.T.
        • Faraone S.V.
        • Pennington B.F.
        Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review.
        Biol Psychiatry. 2005; 57: 1336-1346
        • World Health Organization
        International Classification of Diseases (ICD-10).
        WHO, Geneva1992